adenosine monophosphate has been researched along with tirofiban in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckland, RJ; Holgate, CE; Judge, HM; Storey, RF | 1 |
| Goto, S; Ishida, H; Ruggeri, ZM; Tamura, N | 1 |
| Holmes, CE; Madsen, NJ; Schneider, DJ; Serrano, FA; Sobel, BE | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Boyle, AJ; Danelich, IM; Entwistle, JW; Kabadi, RA; Marhefka, GD; Qureshi, AM; Reeves, G | 1 |
| Avvedimento, M; Billinger, M; Campo, G; Cirillo, P; Esposito, G; Gargiulo, G; Gragnano, F; Heg, D; Hunziker, L; Manavifar, N; Minuz, P; Nagler, M; Piccolo, R; Tebaldi, M; Valgimigli, M; Wahl, A; Windecker, S | 1 |
| Angiolillo, DJ; Bhatt, DL; Stone, GW | 1 |
| Gargiulo, G; Nagler, M; Valgimigli, M | 1 |
| Angiolillo, DJ; Banerjee, S; Bhatt, DL; Cantrell, S; Jones, WS; Mehran, R; Nanna, MG; Ohman, EM; Rao, SV; Rymer, JA; Sullivan, AE; Wang, TY; Washam, JB | 1 |
2 review(s) available for adenosine monophosphate and tirofiban
| Article | Year |
|---|---|
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Topics: Adenosine Monophosphate; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thromboembolism; Tirofiban | 2021 |
1 trial(s) available for adenosine monophosphate and tirofiban
| Article | Year |
|---|---|
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and
Topics: Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
7 other study(ies) available for adenosine monophosphate and tirofiban
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Coagulants; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Secretory Vesicles; Tirofiban; Tyrosine | 2005 |
Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Topics: Adenosine Monophosphate; Blood Platelets; Calcium Channel Blockers; Calcium Signaling; Collagen; Humans; In Vitro Techniques; Lanthanum; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thrombosis; Tirofiban; Tyrosine | 2006 |
Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Benzothiazoles; Blood Platelets; Coronary Disease; Crotalid Venoms; Flow Cytometry; Fluorescent Dyes; Hemostatics; Humans; Lectins, C-Type; Platelet Activating Factor; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Quinolines; Thrombin; Tirofiban; Tyrosine | 2007 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Drug-Eluting Stents; Heart-Assist Devices; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocytopenia; Tirofiban; Treatment Outcome; Ventricular Dysfunction, Left | 2019 |
Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |